Cost-Effectiveness Analysis of Atezolizumab versus Platinum-Based Chemotherapy as First-Line Treatment for Patients with Unresectable Advanced Non-small Cell Lung Cancer with PD-L1 Expression Status in Japan
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost-Effectiveness Analysis of Atezolizumab versus Platinum-Based Chemotherapy as First-Line Treatment for Patients with Unresectable Advanced Non-small Cell Lung Cancer with PD-L1 Expression Status in Japan
Authors
Keywords
-
Journal
CLINICAL DRUG INVESTIGATION
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-10-28
DOI
10.1007/s40261-023-01311-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- First-Line Treatments for Extensive-Stage Small-Cell Lung Cancer With Immune Checkpoint Inhibitors Plus Chemotherapy: A Network Meta-Analysis and Cost-Effectiveness Analysis
- (2022) Shuo Kang et al. Frontiers in Oncology
- Cost-Effectiveness Analysis of Atezolizumab Versus Durvalumab as First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in the USA
- (2022) Yelena Ionova et al. CLINICAL DRUG INVESTIGATION
- Cost-effectiveness Analysis of Atezolizumab Plus Nab-Paclitaxel for Advanced PD-L1 Positive Triple-Negative Breast Cancer in Japan
- (2021) Yugo Chisaki et al. CLINICAL DRUG INVESTIGATION
- Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma
- (2021) Dan Su et al. JAMA Network Open
- First-Line Atezolizumab for Metastatic NSCLC with High PD-L1 Expression: A United States-Based Cost-Effectiveness Analysis
- (2021) Ye Peng et al. ADVANCES IN THERAPY
- Cost-Effectiveness Analysis of Atezolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer With Different PD-L1 Expression Status
- (2021) Guoqiang Liu et al. Frontiers in Oncology
- Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC
- (2021) Jacek Jassem et al. Journal of Thoracic Oncology
- Determining the optimal PD‐1/PD‐L1 inhibitors for the first‐line treatment of non‐small‐cell lung cancer with high‐level PD‐L1 expression in China
- (2021) Meng‐Meng Teng et al. Cancer Medicine
- First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis
- (2021) Qiao Liu et al. Frontiers in Pharmacology
- Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
- (2020) Dong Ding et al. ADVANCES IN THERAPY
- Cost-effectiveness analysis of treatment regimens with obinutuzumab plus chemotherapy in Japan for untreated follicular lymphoma patients
- (2020) Shinya Ohno et al. JOURNAL OF MEDICAL ECONOMICS
- Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
- (2020) Roy S. Herbst et al. NEW ENGLAND JOURNAL OF MEDICINE
- How to Make the Best Use of Immunotherapy as First-Line Treatment for Advanced/Metastatic Non–Small-Cell Lung Cancer
- (2019) Solange Peters et al. ANNALS OF ONCOLOGY
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Development of an Official Guideline for the Economic Evaluation of Drugs/Medical Devices in Japan
- (2017) Takeru Shiroiwa et al. VALUE IN HEALTH
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Health state utilities in non-small cell lung cancer: An international study
- (2016) Beenish Nafees et al. Asia-Pacific Journal of Clinical Oncology
- Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Modeling
- (2016) Claire Williams et al. MEDICAL DECISION MAKING
- Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
- (2015) Gregory A. Masters et al. JOURNAL OF CLINICAL ONCOLOGY
- Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis
- (2014) Marie Westwood et al. HEALTH TECHNOLOGY ASSESSMENT
- Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement
- (2013) Don Husereau et al. VALUE IN HEALTH
- Cost Effectiveness of Personalized Therapy for First-Line Treatment of Stage IV and Recurrent Incurable Adenocarcinoma of the Lung
- (2012) Elizabeth A. Handorf et al. Journal of Oncology Practice
- Health state utilities for non small cell lung cancer
- (2008) Beenish Nafees et al. Health and Quality of Life Outcomes
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started